SELLAS Life Sciences Group (SLS) Stock Overview
A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SLS Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
SELLAS Life Sciences Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.76 |
| 52 Week High | US$15.88 |
| 52 Week Low | US$1.39 |
| Beta | 2.53 |
| 1 Month Change | 58.54% |
| 3 Month Change | 250.59% |
| 1 Year Change | 609.62% |
| 3 Year Change | 852.26% |
| 5 Year Change | 68.30% |
| Change since IPO | -95.60% |
Recent News & Updates
Why Sellas Remains A Strong Sell After Doubling In Price
Summary Sellas Life Sciences has nearly doubled in value, yet fundamentals remain unchanged and do not justify its $2.5B–$3B valuation. The REGAL trial is a high-risk, binary event with a challenging efficacy bar, and delayed events likely reflect stronger control arm performance, not GPS benefit. Even with REGAL success, the AML CR2 market opportunity is niche, making SLS overvalued even on optimistic risk-adjusted NPV assumptions. I maintain a Strong Sell rating on SLS due to asymmetric risk: I think downside on failure is severe, while upside on success is already priced in. Read the full article on Seeking AlphaSELLAS Life Sciences Group (SLS) Stock Looks Fully Valued After $154.6 Million Shelf Filing
Why the new shelf registration matters for SELLAS Life Sciences Group stock SELLAS Life Sciences Group (SLS) has filed a $154.6 million shelf registration covering up to 20,000,000 common shares, an event that puts potential future capital raising firmly on investors’ radar. The filing follows recent shareholder meetings that backed board proposals and an expanded equity plan. This development sets the stage for possible use of this shelf as SELLAS funds its late stage oncology programs and...Recent updates
Shareholder Returns
| SLS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 62.7% | 5.1% | 1.9% |
| 1Y | 609.6% | 40.0% | 20.3% |
Return vs Industry: SLS exceeded the US Biotechs industry which returned 40% over the past year.
Return vs Market: SLS exceeded the US Market which returned 20.3% over the past year.
Price Volatility
| SLS volatility | |
|---|---|
| SLS Average Weekly Movement | 16.7% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SLS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SLS's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 13 | Angelos Stergiou | sellaslifesciences.com |
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK’s WT1 peptide vaccine technology.
SELLAS Life Sciences Group, Inc. Fundamentals Summary
| SLS fundamental statistics | |
|---|---|
| Market cap | US$2.87b |
| Earnings (TTM) | -US$29.46m |
| Revenue (TTM) | n/a |
Is SLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.46m |
| Earnings | -US$29.46m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SLS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/30 15:47 |
| End of Day Share Price | 2026/06/30 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SELLAS Life Sciences Group, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Aydin Huseynov | Ladenburg Thalmann & Company |
| Jason McCarthy | Maxim Group |